Online first
Research paper
Published online: 2024-12-07
Stereotactic body radiation therapy for lung metastases from colorectal cancer: outcomes and prognostic factors in a series of 109 patients
Abstract
Background: Stereotactic body radiotherapy (SBRT) has been applied in the treatment of inoperable lung metastases. We retrospectively evaluated local control (LC) and prognostic factors in patients treated with SBRT for colorectal cancer (CRC) pulmonary metastases.
Materials and methods: Unicentric retrospective study of 109 patients with CRC lung metastases treated with SBRT between 2013 and 2020. The prescribed dose was 30–34 Gy in a single fraction or 40–50 Gy in 4–5 fractions. Primary end-point was LC. Secondary end-points included overall survival (OS), progression-free survival (PFS) and identification of prognostic factors that could influence survival and LC.
Results: Sixty-eight patients presented rectal cancer and 41 colon cancer as primary cancer. Local PFS (LPFS) at 2 years was 81.0%. The median OS was 51 months with a 2-year OS rate of 85.8%. For PFS, 2-year rate was 30.8% and the median PFS was 11.7 months. No patient experienced grade toxicity ≥ 3. Lesion diameter was the only variable marginally significant for LPFS. Metastases located centrally were associated with a worse OS. The volume (≥ 10 cc), the administration of systemic treatment before or after SBRT and the age (≥ 70 years) were predictive factors for PFS. The volume (≥ 10 cc) and the age (≥ 70 years) were predictive factors for regional progression. Extrapulmonary disease was the most important prognostic factor for distance progression.
Conclusions: SBRT proved to be a feasible, safe and effective option for the treatment of patients with CRC lung metastases, with a good LC. None of the prognostic factors studied showed a statistically significant impact on LC.
Keywords: lung metastasiscolorectal cancerlocal controlstereotactic body radiotherapy
References
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209–249.
- Ge Y, Lei S, Cai Bo, et al. Incidence and prognosis of pulmonary metastasis in colorectal cancer: a population-based study. Int J Colorectal Dis. 2020; 35(2): 223–232.
- Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995; 13(1): 8–10.
- Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1): e18–e28.
- Pastorino U, Buyse M, Friedel G, et al. International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113(1): 37–49.
- Lagerwaard FJ, Verstegen NE, Haasbeek CJA, et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012; 83(1): 348–353.
- Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009; 27(10): 1579–1584.
- Agolli L, Bracci S, Nicosia L, et al. Lung Metastases Treated With Stereotactic Ablative Radiation Therapy in Oligometastatic Colorectal Cancer Patients: Outcomes and Prognostic Factors After Long-Term Follow-Up. Clin Colorectal Cancer. 2017; 16(1): 58–64.
- Pasqualetti F, Montrone S, Vivaldi C, et al. Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. Anticancer Res. 2017; 37(1): 315–319.
- Sharma A, Duijm M, Oomen-de Hoop E, et al. Factors affecting local control of pulmonary oligometastases treated with stereotactic body radiotherapy. Acta Oncol. 2018; 57(8): 1031–1037.
- Falcinelli L, Menichelli C, Casamassima F, et al. Stereotactic radiotherapy for lung oligometastases. Rep Pract Oncol Radiother. 2022; 27(1): 23–31.
- Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228–247.
- Frerker B, Hildebrandt G. Distinguishing Radiation Pneumonitis from Local Tumour Recurrence Following SBRT for Lung Cancer. Rep Med Imag. 2020; 20(13): 1–23.
- Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5): 1341–1346.
- Gomez D, Komaki R, Yu J, et al. Radiation therapy definitions and reporting guidelines for thymic malignancies. J Thorac Oncol. 2011; 6(7 Suppl 3): S1743–S1748.
- Huang J, Detterbeck FC, Wang Z, et al. Standard outcome measures for thymic malignancies. J Thorac Oncol. 2010; 5(12): 2017–2023.
- Kumar SS, McGarry RC. Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy. Transl Lung Cancer Res. 2019; 8(Suppl 2): S213–S221.
- Pohar M, Stare J. Relative survival analysis in R. Comput Methods Programs Biomed. 2006; 81(3): 272–278.
- Therneau T. A package for survival analysis in R. R package version 3.5-7. 2023. https://CRAN.R-project.org/package=survival. Last accessed at 10/20/2023.
- Kassambara A, Kosinski M, Biecek P. Survminer: drawing survival curves using “ggplot2”. 2021. R package version 0.4.9. https://CRAN.R-project.org/package=survminer (10.20.2023.).
- Jung J, Song SiY, Kim JH, et al. Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer. Radiat Oncol. 2015; 10: 238.
- Comito T, Cozzi L, Clerici E, et al. Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer. 2014; 14: 619.
- Cao C, Wang D, Tian DH, et al. A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases. J Thorac Dis. 2019; 11(12): 5187–5198.
- Filippi AR, Badellino S, Ceccarelli M, et al. Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study. Int J Radiat Oncol Biol Phys. 2015; 91(3): 524–529.
- Kim MS, Yoo SY, Cho CK, et al. Stereotactic body radiation therapy using three fractions for isolated lung recurrence from colorectal cancer. Oncology. 2009; 76(3): 212–219.
- García-Cabezas S, Bueno C, Rivin E, et al. Lung metastases in oligometastatic patients: outcome with stereotactic body radiation therapy (SBRT). Clin Transl Oncol. 2015; 17(8): 668–672.
- He X, Zhang P, Li Z, et al. Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer: Prognostic Factors for Disease Control and Survival. Am J Clin Oncol. 2018; 41(1): 53–58.
- Schanne DH, Nestle U, Allgäuer M, et al. Stereotactic body radiotherapy for centrally located stage I NSCLC: a multicenter analysis. Strahlenther Onkol. 2015; 191(2): 125–132.
- Ohri N, Tomé WA, Méndez Romero A, et al. Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys. 2021; 110(1): 188–195.
- Pavlidis N, Stanta G, Audisio RA. Cancer prevalence and mortality in centenarians: a systematic review. Crit Rev Oncol Hematol. 2012; 83(1): 145–152.
- Hemminki K, Santi I, Weires M, et al. Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer. 2010; 10: 688.
- O'Connell JB, Maggard MA, Liu JH, et al. Do young colon cancer patients have worse outcomes? World J Surg. 2004; 28(6): 558–562.
- Fu J, Yang J, Tan Y, et al. Young patients (≤ 35 years old) with colorectal cancer have worse outcomes due to more advanced disease: a 30-year retrospective review. Medicine (Baltimore). 2014; 93(23): e135.
- Timmerman RD, Paulus R, Pass HI, et al. Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial. JAMA Oncol. 2018; 4(9): 1263–1266.
- Liu Y, Wang W, Shiue K, et al. Risk factors for symptomatic radiation pneumonitis after stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer. Radiother Oncol. 2021; 156: 231–238.
- Kobayashi N, Abe T, Noda S, et al. Stereotactic body radiotherapy for pulmonar oligometastasis from colorectal cancer. In vivo. 2020; 34: 2991–6.
- Baker R, Han G, Sarangkasiri S, et al. Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung. Int J Radiat Oncol Biol Phys. 2013; 85(1): 190–195.
- Seppenwoolde Y, De Jaeger K, Boersma LJ, et al. Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2003; 55(5): 1331–1340.
- Nakamura T, Fuwa N, Kodaira T, et al. Clinical outcome of stage III non-small-cell lung cancer patients after definitive radiotherapy. Lung. 2008; 186(2): 91–96.
- Londero F, Grossi W, Morelli A, et al. Surgery versus stereotactic radiotherapy for treatment of pulmonary metastases. A systematic review of literature. Future Sci OA. 2020; 6(5): FSO471.